GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (FRA:20B) » Definitions » Retained Earnings

Biomark Diagnostics (FRA:20B) Retained Earnings : €-8.93 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biomark Diagnostics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biomark Diagnostics's retained earnings for the quarter that ended in Dec. 2023 was €-8.93 Mil.

Biomark Diagnostics's quarterly retained earnings declined from Jun. 2023 (€-8.61 Mil) to Sep. 2023 (€-8.73 Mil) and declined from Sep. 2023 (€-8.73 Mil) to Dec. 2023 (€-8.93 Mil).

Biomark Diagnostics's annual retained earnings declined from Mar. 2021 (€-5.74 Mil) to Mar. 2022 (€-7.26 Mil) and declined from Mar. 2022 (€-7.26 Mil) to Mar. 2023 (€-8.18 Mil).


Biomark Diagnostics Retained Earnings Historical Data

The historical data trend for Biomark Diagnostics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Retained Earnings Chart

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.16 -4.86 -5.74 -7.26 -8.18

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.98 -8.18 -8.61 -8.73 -8.93

Biomark Diagnostics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Biomark Diagnostics  (FRA:20B) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Biomark Diagnostics (FRA:20B) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (FRA:20B) Headlines

No Headlines